Shandong Boan Biotechnology Co., Ltd. (HKG:6955)
Hong Kong · Delayed Price · Currency is HKD 2.435
-0.125 (-4.88%)
Sep 18, 2026, 4:08 PM HKT
HKG:6955 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 624.41 | 784.82 | 726.32 | 618.13 | 515.96 | 158.7 | |
Revenue Growth | -17.49% | 8.05% | 17.50% | 19.80% | 225.11% | - |
Cost of Revenue | 198.56 | 222.39 | 183.66 | 209.16 | 161.73 | 52.19 |
Gross Profit | 425.85 | 562.44 | 542.65 | 408.97 | 354.23 | 106.51 |
Selling, General & Admin | 321.68 | 382.08 | 332.3 | 308.22 | 296.42 | 96.21 |
Research & Development | 181.07 | 147.64 | 149.27 | 230.68 | 400.34 | 231.57 |
Operating Expenses | 502.76 | 529.72 | 481.58 | 538.9 | 696.76 | 327.78 |
Operating Income | -76.91 | 32.72 | 61.08 | -129.93 | -342.53 | -221.27 |
Interest Expense | -40.82 | -38.66 | -32.65 | -14.09 | -13.41 | -11.6 |
Interest & Investment Income | 6.81 | 4.49 | 0.41 | 1.16 | 5.57 | 9.1 |
Currency Exchange Gain (Loss) | 1.03 | 1.03 | - | - | 2.38 | - |
Other Non Operating Income (Expenses) | 13.16 | 7.22 | 44.36 | 23.49 | 16.24 | -1.65 |
EBT Excluding Unusual Items | -96.73 | 6.8 | 73.19 | -119.38 | -331.75 | -225.42 |
Other Unusual Items | 0.35 | 0.35 | - | - | - | - |
Pretax Income | -96.38 | 7.14 | 73.19 | -119.38 | -331.75 | -225.42 |
Net Income | -96.38 | 7.14 | 73.19 | -119.38 | -331.75 | -225.42 |
Net Income to Common | -96.38 | 7.14 | 73.19 | -119.38 | -331.75 | -225.42 |
Net Income Growth | - | -90.24% | - | - | - | - |
Shares Outstanding (Basic) | 600 | 576 | 536 | 509 | 499 | 479 |
Shares Outstanding (Diluted) | 600 | 576 | 536 | 509 | 499 | 479 |
Shares Change | 5.47% | 7.40% | 5.23% | 2.14% | 4.19% | 1119.88% |
EPS (Basic) | -0.16 | 0.01 | 0.14 | -0.23 | -0.67 | -0.47 |
EPS (Diluted) | -0.16 | 0.01 | 0.14 | -0.23 | -0.67 | -0.47 |
EPS Growth | - | -90.91% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -7.66 | -184.53 | -85.89 | -283.13 | -354.01 |
Free Cash Flow Per Share | - | -0.01 | -0.34 | -0.17 | -0.57 | -0.74 |
Gross Margin | 68.20% | 71.66% | 74.71% | 66.16% | 68.66% | 67.12% |
Operating Margin | -12.32% | 4.17% | 8.41% | -21.02% | -66.39% | -139.42% |
Profit Margin | -15.43% | 0.91% | 10.08% | -19.31% | -64.30% | -142.04% |
Free Cash Flow Margin | - | -0.98% | -25.41% | -13.89% | -54.87% | -223.06% |
EBITDA | -38.93 | 84.58 | 104.28 | -76.34 | -292.56 | -188.72 |
EBITDA Margin | -6.23% | 10.78% | 14.36% | -12.35% | -56.70% | -118.91% |
D&A For EBITDA | 37.98 | 51.86 | 43.2 | 53.59 | 49.97 | 32.55 |
EBIT | -76.91 | 32.72 | 61.08 | -129.93 | -342.53 | -221.27 |
EBIT Margin | -12.32% | 4.17% | 8.41% | -21.02% | -66.39% | -139.42% |